We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Loss of Function Mutations in GEMIN5 Causes Neurodevelopmental Disorder

By LabMedica International staff writers
Posted on 20 May 2021
Print article
Image: Diagrammatic representation showing the possible mode of disruption in small nuclear ribonucleoproteins (snRNP) complex formation due to loss of GEMIN5 in L1068P and H913R variants
Image: Diagrammatic representation showing the possible mode of disruption in small nuclear ribonucleoproteins (snRNP) complex formation due to loss of GEMIN5 in L1068P and H913R variants
GEMIN5, an RNA-binding protein is essential for assembly of the survival motor neuron (SMN) protein complex and facilitates the formation of small nuclear ribonucleoproteins (snRNPs), the building blocks of spliceosomes.

Perturbing the physiological functions of RNA-binding proteins (RBPs) can lead to motor neuron diseases such as amyotrophic lateral sclerosis, and spinal muscular atrophy (SMA) among others. RBPs are critical for regulating multiple molecular functions including splicing, localization, translation, and mRNA stability.

An international group of collaborators led by Pediatricians at the Children's Hospital of Pittsburgh (Pittsburgh, PA, USA) contacted pediatricians, geneticists and neurologists from all over the globe, eventually collecting data from 30 patient families in 12 different countries. The team used genomic DNA from the proband as well as parents and siblings, when available, the exonic regions and flanking splice junctions of the genome were captured using the SureSelect Human All Exon V4 (50 Mb), the Clinical Research Exome kit (Agilent Technologies, Santa Clara, CA, USA) or the IDT x Gen Exome Research Panel v1.0 (Integrated DNA Technologies, Inc, Coralville, Iowa, USA). Massively parallel sequencing was done on a HiSeq2000 system (Illumina, San Diego, CA, USA) with 100 bp or greater paired end reads.

The scientists identified 30 affected individuals from 22 unrelated families presenting with developmental delay, hypotonia, and cerebellar ataxia harboring biallelic variants in the GEMIN5 gene. Mutations in GEMIN5 perturb the subcellular distribution, stability, and expression of GEMIN5 protein and its interacting partners in patient induced pluripotent stem cell lines (iPSC)-derived neurons, suggesting a potential loss-of-function mechanism. GEMIN5 mutations result in disruption of snRNP complex assembly formation in patient iPSC neurons.

Deepa S. Rajan, MD, an assistant professor of pediatrics and a senior author of the study, said, “Children came into the clinic with non-specific symptoms, such as developmental delay and abnormal gait. Their doctors ran all the possible tests, including assessing a child's metabolic function, to no avail--their conditions had no easy explanation. It was not until we did an extensive genome analysis that we found that these patients had mutations in the GEMIN5 gene.”

The authors concluded that their findings collectively provide evidence that pathogenic variants in GEMIN5 perturb physiological functions and result in a neurodevelopmental delay and ataxia syndrome. Also that biallelic variants in GEMIN5 cause developmental delay, motor dysfunction, and cerebellar atrophy and reduce snRNP complex assembly proteins, impair snRNP assembly and misregulate RNA targets. The study was published on May 7, 2021 in the journal Nature Communications.

Related Links:
Children's Hospital of Pittsburgh
Agilent Technologies
Integrated DNA Technologies
Illumina


Gold Supplier
Blood Glucose Laboratory Analyzer
Nova Primary
New
Silver Supplier
Dyspeptic Diagnostic Test
GastroPanel
New
Sepsis Detection Test
SeptiCyte RAPID
New
Next-Generation Sequencing (NGS) Workstation
NGS STAR for COVID-19

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.